SEMINARIOS PARA DICIEMBRE
Thursday, December 12, 2013
Wednesday, November 6, 2013
El taller Matemáticas para Chicos
( jovenes que cursen 6to a 11 mo grado)
es el próximo sábado 9 de noviembre de 8:00 - 3:00 p.m
EDP University
Ave. Ponce de León 560
Reservaciones 787-810-7868
El mismo contiene los principios básicos del Neuroaprendizaje además de matemáticas
El seminario va dirigido a qué el participante se relacione de manera diferente con las matemáticas, ejercicios distintos a lo que hacen regularmente para que pierdan el miedo y pueda ver alternativas en su relación con las matemáticas.
Inversión $75.00
Además ofreceremos el taller de Neurosanación, este es para adultos, dirigido a la conocimiento del cuerpo, salud optima y por lo tanto prevencion de las enfermedades
En el
EDP University
Ave. Ponce de León 560
8:00a. m a 5:00 pm
Reservaciones 787-810-7868
Thursday, October 24, 2013
NEUROAPRENDIZAJE®
2 y 3 de noviembre de 2013
8:00 a.m. – 5:00 p.m.
EDP University
560 Ave. Ponce de León
Hato Rey, Puerto Rico
Llamar al 787-810-7868
Wednesday, September 18, 2013
Optimizacion Cognitiva
Este sábado
EDP University
260 Ave Ponce de Leon
entre las intersecciones de la calle Guayama y calle Mayaguez
Llama HAZ TU RESERVA AHORA- deja mensaje o envia mensaje de Texto
787-810-7868
21 de septiembre de 2013
8:00 A.M. - 5:00 P.M.
Ofreceremos el Seminario de Optimizacion Cognitiva Y...
QUIERES DISFRUTAR TU VIDA A PLENITUD?
EDP University
260 Ave Ponce de Leon
entre las intersecciones de la calle Guayama y calle Mayaguez
Llama HAZ TU RESERVA AHORA- deja mensaje o envia mensaje de Texto
787-810-7868
Monday, August 26, 2013
Increased risk of sleep disorder in children who received swine flu vaccine
Tuesday, February 26, 2013 - 10:34
Research: Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis
A study published on bmj.com today finds an increased risk of narcolepsy in children and adolescents who received the A/H1N1 2009 influenza vaccine (Pandemrix) during the pandemic in England.
The results are consistent with previous studies from Finland and Sweden and indicate that the association is not confined to Scandinavian populations. However, the authors stress that the risk may still be overestimated, and they call for longer term monitoring of the cohort of children and adolescents exposed to Pandemrix to evaluate the exact level of risk.
In 2009, pandemic influenza A (H1N1) virus spread rapidly, resulting in millions of cases and over 18,000 deaths in over 200 countries. In England the vaccine Pandemrix was introduced in October 2009. By March 2010, around one in four (24%) of healthy children aged under 5 and just over a third (37%) aged 2-15 in a risk group had been vaccinated.
In August 2010 concerns were raised in Finland and Sweden about a possible association between narcolepsy and Pandemrix. And in 2012 a study from Finland reported a 13-fold increased risk in children and young people aged 4-19.
But a lack of reported cases in other countries led to speculation that any possible association might be restricted to these Scandinavian populations.
Narcolepsy is a chronic disorder of excessive daytime sleepiness, often accompanied by sudden muscle weakness triggered by strong emotion (known as cataplexy). To evaluate the risk after vaccination in England, a team of researchers reviewed case notes for 245 children and young people aged 4-18 from sleep centres and child neurology centres across England.
Of these, 75 had narcolepsy (56 with cataplexy) with onset after 1 January 2008. Eleven had been vaccinated before onset of symptoms; seven within six months.
After adjusting for clinical conditions, vaccination at any time was associated with a 14-fold increased risk of narcolepsy, whereas vaccination within six months before onset was associated with a 16-fold increased risk.
In absolute numbers, this means that one in 52,000 to 57,500 doses are associated with narcolepsy, say the authors.
They write: “The increased risk of narcolepsy after vaccination with ASO3 adjuvanted pandemic A/H1N1 2009 vaccine indicates a causal association, consistent with findings from Finland. Because of variable delay in diagnosis, however, the risk might be overestimated by more rapid referral of vaccinated children.”
While further use of this vaccine for prevention of seasonal flu seems unlikely, they say their findings “have implications for the future licensure and use of AS03 adjuvanted pandemic vaccines containing different subtypes such H5 or H9.”
And they conclude: “Further studies to assess the risk, if any, associated with the other A/H1N1 2009 vaccines used in the pandemic, including those with and without adjuvants, are also needed to inform the use of such vaccines in the event of a future pandemic.”
Contact:
Elizabeth Miller, Consultant Epidemiologist, Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency, Colindale, London, UK
Contact with Liz Miller via Georgina Fletcher in the HPA press office. Tel: +44 (0)208 327 6690
Email: georgina.fletcher@hpa.org.uk
A study published on bmj.com today finds an increased risk of narcolepsy in children and adolescents who received the A/H1N1 2009 influenza vaccine (Pandemrix) during the pandemic in England.
The results are consistent with previous studies from Finland and Sweden and indicate that the association is not confined to Scandinavian populations. However, the authors stress that the risk may still be overestimated, and they call for longer term monitoring of the cohort of children and adolescents exposed to Pandemrix to evaluate the exact level of risk.
In 2009, pandemic influenza A (H1N1) virus spread rapidly, resulting in millions of cases and over 18,000 deaths in over 200 countries. In England the vaccine Pandemrix was introduced in October 2009. By March 2010, around one in four (24%) of healthy children aged under 5 and just over a third (37%) aged 2-15 in a risk group had been vaccinated.
In August 2010 concerns were raised in Finland and Sweden about a possible association between narcolepsy and Pandemrix. And in 2012 a study from Finland reported a 13-fold increased risk in children and young people aged 4-19.
But a lack of reported cases in other countries led to speculation that any possible association might be restricted to these Scandinavian populations.
Narcolepsy is a chronic disorder of excessive daytime sleepiness, often accompanied by sudden muscle weakness triggered by strong emotion (known as cataplexy). To evaluate the risk after vaccination in England, a team of researchers reviewed case notes for 245 children and young people aged 4-18 from sleep centres and child neurology centres across England.
Of these, 75 had narcolepsy (56 with cataplexy) with onset after 1 January 2008. Eleven had been vaccinated before onset of symptoms; seven within six months.
After adjusting for clinical conditions, vaccination at any time was associated with a 14-fold increased risk of narcolepsy, whereas vaccination within six months before onset was associated with a 16-fold increased risk.
In absolute numbers, this means that one in 52,000 to 57,500 doses are associated with narcolepsy, say the authors.
They write: “The increased risk of narcolepsy after vaccination with ASO3 adjuvanted pandemic A/H1N1 2009 vaccine indicates a causal association, consistent with findings from Finland. Because of variable delay in diagnosis, however, the risk might be overestimated by more rapid referral of vaccinated children.”
While further use of this vaccine for prevention of seasonal flu seems unlikely, they say their findings “have implications for the future licensure and use of AS03 adjuvanted pandemic vaccines containing different subtypes such H5 or H9.”
And they conclude: “Further studies to assess the risk, if any, associated with the other A/H1N1 2009 vaccines used in the pandemic, including those with and without adjuvants, are also needed to inform the use of such vaccines in the event of a future pandemic.”
Contact:
Elizabeth Miller, Consultant Epidemiologist, Immunisation, Hepatitis and Blood Safety Department, Health Protection Agency, Colindale, London, UK
Contact with Liz Miller via Georgina Fletcher in the HPA press office. Tel: +44 (0)208 327 6690
Email: georgina.fletcher@hpa.org.uk
Sunday, August 25, 2013
7 y 8 de septiembre
de 2013
Seminario de
Neuroaprendizaje™
EDP University
8:00- 5:00
Reserva tu espacio
Llama Ahora !!!!
787-810-7868
Talleres:
Todos nuestros talleres se basan en los más recientes adelantos y descubrimientos de la Neurociencia Cognitiva. Esta rama de la Neurociencia estudia la estructura y funcionamiento del cerebro. Utilizando estos conocimientos podemos darle al cerebro el mejor cuidado para obtener el mayor rendimiento y resultados de excelencia.
NeuroAprendizaje : Los conocimientos de la neurociencia cognitiva
aplicados al área del crecimiento y desarrollo personal para ser exitoso en las
siete áreas fundamentales de la vida: El área Física, Mental, Espiritual,
Familiar, Profesional, Social y Financiera. En el taller de NeuroAprendizaje:
·
Aprendes la
estructura y función de tu cerebro y cómo desarrollar tu genialidad.
·
Fotolectura,
Memoria, Comprensión y Aprendizaje Acelerado- Las más poderosas herramientas
para alcanzar tus metas y objetivos profesionales.
·
Aprende a
desarrollar un Plan Estratégico de Accion para alcanzar el Exito y vive la
emoción de ser líder en vez de seguidor.
Monday, August 19, 2013
NeuroAprendizaje :
|
787-810-7868
PONCE NEUROAPRENDIZAJE AGOSTO
NEUROAPRENDIZAJE™
Estaremos en Ponce esta semana
Jueves 22 de
agosto de 2013
6:30 p.m.
Libreria Paliques
(787) 651-7365
1802 Alcazar Street, Edif. Alcazar
Ponce, PR
Ponce, PR
Además ….
SEMINARIO
SABADO 24 Y DOMINGO 25
DE DOS DIAS
APROVECHA
RESERVA TU ESPACIO AHORA
LLAMA AL
787-810-7868
Subscribe to:
Posts (Atom)